MediPharm Labs Corp.
LABS.TO
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 7.18M | 7.56M | 7.25M | 6.71M | 6.34M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.18M | 7.56M | 7.25M | 6.71M | 6.34M |
| Cost of Revenue | 4.83M | 4.98M | 4.86M | 3.30M | 3.10M |
| Gross Profit | 2.36M | 2.58M | 2.38M | 3.41M | 3.24M |
| SG&A Expenses | 4.00M | 4.28M | 4.38M | 1.71M | 4.66M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 150.30K | 30.70K | -138.00K | -94.10K | -32.80K |
| Total Operating Expenses | 9.07M | 9.33M | 9.16M | 5.02M | 7.77M |
| Operating Income | -1.89M | -1.77M | -1.91M | 1.69M | -1.43M |
| Income Before Tax | -2.03M | -1.89M | -2.68M | -2.38M | -3.23M |
| Income Tax Expenses | -- | -- | -- | -200.70K | -2.20K |
| Earnings from Continuing Operations | -2.03M | -1.89M | -2.68M | -2.18M | -3.23M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.03M | -1.89M | -2.68M | -2.18M | -3.23M |
| EBIT | -1.89M | -1.77M | -1.91M | 1.69M | -1.43M |
| EBITDA | -1.51M | -1.25M | -1.34M | 2.20M | -971.40K |
| EPS Basic | 0.00 | 0.00 | -0.01 | 0.00 | -0.01 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | -0.01 | 0.00 | -0.01 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 411.07M | 404.78M | 403.68M | 441.50M | 398.52M |
| Average Diluted Shares Outstanding | 411.07M | 404.78M | 403.68M | 441.50M | 398.52M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
